Michael Rowbotham
Directeur/Membre du Conseil chez The University of California, San Francisco
Profil
Michael Rowbotham has been Chief Medical Officer of Adamas Pharmaceuticals, Inc. since June, 2006.
He is Professor of Neurology and a Director of the Pain Research Center and the Clinical Research, Ernest Gallo Clinic and Research Center at the University of California, San Francisco (UCSF).
Dr. Rowbotham received his BA degree in Biology from the University of California, San Diego and an MD from the University of California, San Francisco.
Postes actifs de Michael Rowbotham
| Sociétés | Poste | Début |
|---|---|---|
| The University of California, San Francisco | Directeur/Membre du Conseil | - |
Anciens postes connus de Michael Rowbotham
| Sociétés | Poste | Fin |
|---|---|---|
| ADAMAS PHARMACEUTICALS, INC. | Directeur Technique/Scientifique/R&D | - |
Formation de Michael Rowbotham
| The University of California, San Francisco | Doctorate Degree |
| University of California San Diego | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 1 |
|---|---|
Adamas Pharmaceuticals LLC
 Adamas Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Adamas Pharmaceuticals, Inc. engages in discovery and development of chrono-synchronous therapies for chronic neurologic disorders. Its products include GOCOVRI, ADS-5012, ADS-4101, and Namzaric. GOCOVRI is indicated for the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy. ADS-5102 is a treatment for walking impairment in patients with multiple sclerosis. ADS-401 treats partial onset seizures in patients with epilepsy. Namzaric is a drug treatment for moderate to severe Alzheimer's disease. The company was founded by Gregory T. Went on November 15, 2000 and is headquartered in Emeryville, CA. | Health Technology |